- January 25, 2022Annovis Bio Announces Positive FDA Feedback for Buntanetap Phase 3 Clinical Development in Parkinson's Disease
- January 10, 2022Annovis Bio Enhances Leadership Team with Two Senior Appointments
- January 5, 2022Annovis Bio Announces Official Unique Name Buntanetap for Lead Candidate ANVS401
- October 01, 2019Axonal Transport and Neurological Disease
- May 21, 2019How did the amyloid hypothesis go from promising to perilous in the search for Alzheimer’s treatments?
- April 30, 2019After amyloid failures, it’s time to take a new tack for treating Alzheimer’s
Back to Top